The research group led by Prof. Alex Schier, Director of the University of Basel’s Biozentrum, has identified 30 genes associated with schizophrenia.
The team was able to show which pathological changes in the brain and behavioral abnormalities are triggered by these genes. The results of the study have now been published in Cell.
The research team led by Prof. Alex Schier, Director of the Biozentrum, University of Basel, and currently group leader at Harvard University in Cambridge, investigated a total of 132 genes associated with schizophrenia. The potential connection to schizophrenia was confirmed for 30 genes. In zebrafish, the researchers found that errors in these genes impair the development or function of the brain and lead to behavioral abnormalities.
Regions in the genome under suspicion
Schizophrenia is a psychosis that leads to a disturbed perception of reality. This includes hearing voices, hallucinations or delusions. Although the disease can be treated with medication, it is currently incurable. Genetic changes that manifest themselves in the brain can cause schizophrenia. Previous studies have shown that several regions of the genome containing a variety of genes are associated with the disease.
Perpetrator profile of 30 genes
Alex Schier’s team has now identified 30 genes in these regions and has been able to show that they have concrete effects on the structure and function of the brain as well as on various behavioral patterns. “Of the 132 suspects, we were ultimately able to establish a more precise perpetrator profile for 30 genes,” said Schier. “One of the perpetrators is the transcription factor znf536, which controls the development of the forebrain. This brain region influences our social behavior and the processing of stress.” The research team not only deciphered the function of the individual genes, but also generated an atlas of all genes with their respective consequences for the brain.
In the crosshair of research
“The question of how the individual genes trigger schizophrenia remains open,” says Schier. “It would be possible to investigate whether the genes we identified change similar brain regions in patients as in zebrafish.” These genes and brain regions could then become new targets for drug therapies.
Learn more: Crime scene schizophrenia — 30 genes under suspicion
The Latest on: Schizophrenia
[google_news title=”” keyword=”schizophrenia” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Schizophrenia
- Teva Stock Powers Ahead as Schizophrenia News Offsets Mixed Earningson May 8, 2024 at 11:10 am
Shares of Teva Pharmaceutical Industries were climbing yet again on Wednesday, after the company announced positive results in a trial of a schizophrenia medicine. Its quarterly results, also ...
- Cat owners could be at higher risk of schizophrenia, study suggestson May 8, 2024 at 10:58 am
Snuggling with a cat seems like a loving and relaxing activity, but a new study implies that it might affect your mental health down the line.
- Generics Player Teva Pharmaceutical Aces Late-Stage Schizophrenia Drug Study, Stock Shoots Higheron May 8, 2024 at 10:49 am
PANSS measures the symptom severity of schizophrenia. TEV-‘749 utilizes SteadyTeq, a copolymer technology proprietary to Medincell that provides a controlled, steady release of olanzapine, the most ...
- How BI humanizes schizophrenia experience in return of popup exhibiton May 8, 2024 at 7:28 am
Boehringer Ingelheim brought its latest iteration of Look Beyond Stable, an immersive exhibit showing how people with schizophrenia live, back to New York.
- Teva Pharmaceutical’s stock climbs as schizophrenia treatment shows promiseon May 8, 2024 at 6:15 am
Teva Pharmaceutical Industries stock jumped more than 6% early Wednesday after the company reported first-quarter sales that topped estimates and released positive late-stage trial data on a ...
- Teva And Medincell Say Phase 3 SOLARIS Study In Schizophrenia Met Primary Goalon May 8, 2024 at 4:43 am
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), and Medincell Wednesday said the Phase 3 ...
- Teva, Medincell's schizophrenia drug succeeds in late-stage studyon May 8, 2024 at 4:25 am
Israel-based Teva Pharmaceuticals , TEVA.N and French partner Medincell said on Wednesday their experimental schizophrenia drug had met its main goal of reducing the severity of symptoms in a ...
- Long-Acting Subcutaneous Olanzapine Effective in Schizophrenia Trialon May 7, 2024 at 5:00 pm
A once-monthly subcutaneous formulation of olanzapine (TEV-’749) was found to improve symptoms in patients with schizophrenia without post injection delirium syndrome (PDSS). Using a proprietary ...
- 'Impressive' New Data on Novel Schizophrenia Hopeful KarXTon May 7, 2024 at 5:00 pm
Results of the EMERGENT-3 trial confirm that the novel investigational antipsychotic xanomeline-trospium (KarXT, Karuna Therapeutics) is effective and well tolerated in adults with schizophrenia ...
- New study into identical twins suggests a possible treatment for people with schizophrenia disorderon May 7, 2024 at 4:11 pm
Research led by Prof. Shani Stern at the University of Haifa unveils genetic discrepancies in schizophrenia discordant monozygotic twins, offering insights for treatment.
via Bing News